BeyondSpring Inc.

BeyondSpring Inc. (Nasdaq: BYSI) is a clinical-stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs in oncology. The company's website is www.beyondspringpharma.com.

The company's lead asset is Plinabulin, a first-in-class novel small molecule derived from marine microorganisms that functions as a Selective Immunomodulating Microtubule-Binding Agent. Plinabulin has been administered to over 700 cancer patients and operates through a dual mechanism: dendritic cell maturation leading to tumor antigen-specific T-cell activation for anti-cancer benefit, and early-onset chemotherapy-induced neutropenia prevention through hematopoietic stem cell mobilization. The company has completed a Phase 3 registration study (DUBLIN-3) in second- and third-line non-small cell lung cancer with EGFR wild type, demonstrating statistically significant overall survival benefit with an 82 percent reduction in grade 4 neutropenia. BeyondSpring is planning a confirmatory global Phase 3 study targeting patients who have progressed on prior immune checkpoint inhibitors, addressing a severe unmet medical need where over 60 percent of patients develop acquired resistance to current therapies.

Beyond Plinabulin, the company is developing three small molecule immune agents currently in preclinical stages. BeyondSpring also founded and maintains an equity stake in SEED Therapeutics Inc., which utilizes a proprietary Targeted Protein Degradation platform to develop therapeutic agents. SEED has advanced a novel RBM39 degrader into Phase 1 clinical studies and maintains partnerships with Eli Lilly and Eisai for oncology and central nervous system disease applications.

The company maintains principal executive offices in New Jersey with additional offices in Beijing and Dalian, China, and is incorporated in the Cayman Islands. BeyondSpring's management team brings deep expertise in biology, chemistry, drug discovery, manufacturing, clinical development, regulatory affairs, and capital markets. The company is pursuing multiple investigator-initiated studies exploring Plinabulin combinations with immunotherapy agents and chemotherapy across various cancer indications including NSCLC, small cell lung cancer, head-and-neck cancer, and Hodgkin's lymphoma.